Geographical/Interracial Differences in Polymorphic Drug Oxidation
- 1 September 1995
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 29 (3), 192-209
- https://doi.org/10.2165/00003088-199529030-00005
Abstract
The isoenzymes which catalyse the polymorphic hydroxylations of debrisoquine/sparteine and S-mephenytoin are cytochromes P450 2D6 and P450 2C19 (CYP2D6 and CYP2C19), respectively. CYP2D6 is involved...Keywords
This publication has 85 references indexed in Scilit:
- Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean populationPharmacogenetics, 1993
- Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolismPharmacogenetics, 1993
- Genetically variable metabolism of antidepressants and neuroleptic drugs in manPharmacogenetics, 1993
- Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsPharmacogenetics, 1992
- Interethnic variation of drug metabolismTrends in Pharmacological Sciences, 1991
- Ethnic Differences in Drug Disposition and ResponsivenessClinical Pharmacokinetics, 1991
- Differences in Drug Metabolism Polymorphism Between Orientals and CaucasiansDrug Metabolism Reviews, 1990
- LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATIONThe Lancet, 1987
- Ethnic Differences in Drug MetabolismClinical Pharmacokinetics, 1982
- A study of the debrisoquine hydroxylation polymorphism in a Nigerian populationXenobiotica, 1980